Pulmonary toxicity of anticancer therapy from childhood Hodgkin’s lymphoma
- Authors: Kulyova S.A.1, Belogurova M.B.2, Ivanova S.V.1, Melnik L.I.1
-
Affiliations:
- N.N. Petrov Research Institute of Oncology
- St. Petersburg State Pediatric Medical University
- Issue: Vol 6, No 4 (2015)
- Pages: 135-139
- Section: Articles
- URL: https://journals.rcsi.science/pediatr/article/view/1380
- DOI: https://doi.org/10.17816/PED64135-139
- ID: 1380
Cite item
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Svetlana Aleksandrovna Kulyova
N.N. Petrov Research Institute of Oncology
Email: deton.hospital31@inbox.ru
MD, PhD, Dr Med Sci, Professor, Head. Department of Children`s Chemotherapy and Combined Modality Therapy
Margarita Borisovna Belogurova
St. Petersburg State Pediatric Medical University
Email: deton.hospital31@inbox.ru
MD, PhD, Dr Med Sci, Professor, Head. Department of Oncology, Pediatric oncology and Radiation therapy
Svetlana Viacheslavovna Ivanova
N.N. Petrov Research Institute of Oncology
Email: deton.hospital31@inbox.ru
Department of Children`s Chemotherapy and Combined Modality Therapy
Larisa Ivanovna Melnik
N.N. Petrov Research Institute of Oncology
Email: deton.hospital31@inbox.ru
Researcher
References
- Bauer K. A., Skarin A. T., Balikian J. Pulmonary complication associated with combination chemotherapy programs containing bleomycin. Am. J. Med. 1983; 74: 557-63.
- Bossi G., Cerveri I., Volpini E. Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease. Ann. Oncol. 1997; 8: 19-24.
- Fryer C. J., Hutchinson R. J., Krailo M. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group. J. Clin. Oncol. 1990; 8: 1971-80.
- Hunger S. P., Link M. P., Donaldson S. S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J. Clin. Oncol. 1994; 12: 2160-6.
- Marina N. M., Greenwald C. A., Fairclough D. L. Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer. 1995; 75: 1706-11.
- Levi J. A., Raghavan D., Harvey V. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J. Clin. Oncol. 1993; 11: 1300-5.
- Lund M. B., Kongerud J., Nome O. Lung function impairment in long-term survivors of Hodgkin's disease. An. Oncol. 1995; 6: 495-501.
- Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001; 120: 617-24.
- Tashiro M., Izumikawa K., Yoshioka D. Lung fibrosis 10 years after cessation of bleomycin therapy. Tohoku J. Exp. Med. 2008; 216: 77-80.
- Uzer I., Ozgurolgu M., Uzer B. Delayed onset bleomycin-induced pneumonitis. Urology. 2005; 66: 23-5.